Healthcare provider profile · identity verified

Patricia Coyle

Internal Medicine · PITTSBURGH, PA · NPI 1801868476

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	592	181
Levothyroxine Sodium	Levothyroxine Sodium	318	85
Lisinopril	Lisinopril	290	91
Rosuvastatin Calcium	Rosuvastatin Calcium	240	76
Omeprazole	Omeprazole	206	66
Losartan Potassium	Losartan Potassium	194	62
Amlodipine Besylate	Amlodipine Besylate	179	59
Hydrochlorothiazide	Hydrochlorothiazide	156	50
Atenolol	Atenolol	104	32
Metoprolol Succinate	Metoprolol Succinate	103	36
Famotidine	Famotidine	89	32
Sertraline Hcl	Sertraline Hcl	80	27
Eliquis	Apixaban	79	24
Alprazolam	Alprazolam	74	38
Escitalopram Oxalate	Escitalopram Oxalate	73	19
Metformin Hcl	Metformin Hcl	72	24
Simvastatin	Simvastatin	70	24
Gabapentin	Gabapentin	69	18
Pantoprazole Sodium	Pantoprazole Sodium	68	22
Metoprolol Tartrate	Metoprolol Tartrate	66	17
Synthroid	Levothyroxine Sodium	66	14
Potassium Chloride	Potassium Chloride	58	18
Tamsulosin Hcl	Tamsulosin Hcl	57	18
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	57	17
Alendronate Sodium	Alendronate Sodium	55	17
Ozempic	Semaglutide	54	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	52	16
Meloxicam	Meloxicam	52	17
Duloxetine Hcl	Duloxetine Hcl	51	13
Trazodone Hcl	Trazodone Hcl	49	14
Carvedilol	Carvedilol	48	12
Furosemide	Furosemide	46	17
Zolpidem Tartrate	Zolpidem Tartrate	44	16
Prednisone	Prednisone	42	17
Fluticasone Propionate	Fluticasone Propionate	39	17
Albuterol Sulfate Hfa	Albuterol Sulfate	38	14
Montelukast Sodium	Montelukast Sodium	38	15
Finasteride	Finasteride	37	suppressed
Bupropion Hcl Sr	Bupropion Hcl	36	14
Lorazepam	Lorazepam	34	14
Clonazepam	Clonazepam	33	11
Xarelto	Rivaroxaban	33	suppressed
Spironolactone	Spironolactone	32	12
Pravastatin Sodium	Pravastatin Sodium	31	suppressed
Citalopram Hbr	Citalopram Hydrobromide	29	suppressed
Donepezil Hcl	Donepezil Hcl	27	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	25	suppressed
Celecoxib	Celecoxib	24	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	24	suppressed
Ropinirole Hcl	Ropinirole Hcl	23	suppressed
Jardiance	Empagliflozin	22	suppressed
Tramadol Hcl	Tramadol Hcl	22	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Allopurinol	Allopurinol	18	suppressed
Baclofen	Baclofen	17	suppressed
Ezetimibe	Ezetimibe	17	suppressed
Felodipine Er	Felodipine	17	suppressed
Metformin Hcl Er	Metformin Hcl	17	suppressed
Ibuprofen	Ibuprofen	16	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	16	13
Nystatin	Nystatin	15	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	15	suppressed
Valsartan	Valsartan	15	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	14	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	14	suppressed
Meclizine Hcl	Meclizine Hcl	14	suppressed
Azithromycin	Azithromycin	13	13
Ibu	Ibuprofen	13	suppressed
Irbesartan	Irbesartan	13	suppressed
Mounjaro	Tirzepatide	13	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Warfarin Sodium	Warfarin Sodium	13	suppressed
Balsalazide Disodium	Balsalazide Disodium	12	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	suppressed
Premarin	Estrogens, Conjugated	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	11	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Clobetasol Propionate	Clobetasol Propionate	11	suppressed
Dilt-Xr	Diltiazem Hcl	11	suppressed
Estradiol	Estradiol	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Glipizide Er	Glipizide	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error